Skip to main content
Top
Published in: BMC Neurology 1/2013

Open Access 01-12-2013 | Research article

Cerebral hemodynamics and endothelial function in patients with Fabry disease

Authors: Tomás Segura, Oscar Ayo-Martín, Isabel Gómez-Fernandez, Carolina Andrés, Miguel A Barba, José Vivancos

Published in: BMC Neurology | Issue 1/2013

Login to get access

Abstract

Background

Cerebral vasculopathy have been described in Fabry disease, in which altered cerebral blood flow, vascular remodelling or impairment of endothelial function could be involved. Our study aims to evaluate these three possibilities in a group of Fabry patients, and compare it to healthy controls.

Methods

Cerebral hemodynamics, vascular remodelling and systemic endothelial function were investigated in 10 Fabry patients and compared to data from 17 healthy controls. Transcranial Doppler was used to study blood flow velocity of intracranial arteries and cerebral vasomotor reactivity. For the study of vascular remodelling and endothelial function, intima-media thickness of common carotid arteries, flow-mediated dilation in brachial artery and serum levels of soluble VCAM-1, TNF-α, high-sensitive CRP and IL-6 were measured. Differences between groups were evaluated using appropriate tests.

Results

No relevant differences were observed in cerebral hemodynamic parameters, intima-media thickness or flow-mediated dilation. There was a trend for low serum levels of IL-6 and high serum levels of TNF-α and high-sensitive CRP in Fabry patients; plasma concentrations of soluble VCAM-1 were significantly higher in Fabry disease patients than in healthy volunteers (p = 0.02).

Conclusions

In our sample, we did not find relevant alterations of cerebral hemodynamics in Fabry disease patients. Increased levels of plasmatic endothelial biomarkers seem to be the most important feature indicative of possible vascular dysfunction in Fabry disease patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011, 11: 61-10.1186/1471-2377-11-61.CrossRefPubMedPubMedCentral Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011, 11: 61-10.1186/1471-2377-11-61.CrossRefPubMedPubMedCentral
2.
go back to reference Celtikci B, Topçu M, Ozkara HA: Two novel alpha-galactosidase a mutations causing fabry disease: a missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man. Clin Biochem. 2011, 44: 809-812. 10.1016/j.clinbiochem.2011.04.022.CrossRefPubMed Celtikci B, Topçu M, Ozkara HA: Two novel alpha-galactosidase a mutations causing fabry disease: a missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man. Clin Biochem. 2011, 44: 809-812. 10.1016/j.clinbiochem.2011.04.022.CrossRefPubMed
3.
go back to reference Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al: Fabry disease 'The New great Imposter’: results of the French observatoire in internal medicine departments (FIMeD). Clin Genet. 2012, 81: 571-577. 10.1111/j.1399-0004.2011.01718.x.CrossRefPubMed Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al: Fabry disease 'The New great Imposter’: results of the French observatoire in internal medicine departments (FIMeD). Clin Genet. 2012, 81: 571-577. 10.1111/j.1399-0004.2011.01718.x.CrossRefPubMed
4.
go back to reference Altarescu G, Elstein D: Fabry disease in an oligosymptomatic male. Isr Med Assoc J. 2011, 13: 191-192.PubMed Altarescu G, Elstein D: Fabry disease in an oligosymptomatic male. Isr Med Assoc J. 2011, 13: 191-192.PubMed
6.
go back to reference Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al: Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010, 41: 863-868. 10.1161/STROKEAHA.110.579409.CrossRefPubMed Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al: Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010, 41: 863-868. 10.1161/STROKEAHA.110.579409.CrossRefPubMed
7.
go back to reference Alfadhel M, Sirrs S: Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag. 2011, 7: 69-82.PubMedPubMedCentral Alfadhel M, Sirrs S: Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag. 2011, 7: 69-82.PubMedPubMedCentral
8.
go back to reference Salviati A, Burlina AP, Borsini W: Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010, 31: 299-306. 10.1007/s10072-009-0211-y.CrossRefPubMedPubMedCentral Salviati A, Burlina AP, Borsini W: Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010, 31: 299-306. 10.1007/s10072-009-0211-y.CrossRefPubMedPubMedCentral
9.
go back to reference Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, et al: Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011, 34: 605-619. 10.1007/s10545-011-9308-6.CrossRefPubMedPubMedCentral Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, et al: Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J Inherit Metab Dis. 2011, 34: 605-619. 10.1007/s10545-011-9308-6.CrossRefPubMedPubMedCentral
10.
go back to reference Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005, 366: 1794-1796. 10.1016/S0140-6736(05)67635-0.CrossRefPubMed Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005, 366: 1794-1796. 10.1016/S0140-6736(05)67635-0.CrossRefPubMed
11.
go back to reference MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001, 38: 769-775. 10.1136/jmg.38.11.769.CrossRefPubMedPubMedCentral MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001, 38: 769-775. 10.1136/jmg.38.11.769.CrossRefPubMedPubMedCentral
12.
go back to reference Kolodny EH, Pastores GM: Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol. 2002, 13 (Suppl 2): S150-S153.PubMed Kolodny EH, Pastores GM: Anderson-Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol. 2002, 13 (Suppl 2): S150-S153.PubMed
13.
go back to reference Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H: Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004, 251: 564-570. 10.1007/s00415-004-0364-9.CrossRefPubMed Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H: Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004, 251: 564-570. 10.1007/s00415-004-0364-9.CrossRefPubMed
14.
go back to reference Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001, 104: 1506-1512. 10.1161/hc3801.096352.CrossRefPubMed Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001, 104: 1506-1512. 10.1161/hc3801.096352.CrossRefPubMed
15.
go back to reference Azevedo E, Mendes A, Seixas D, Santos R, Castro P, Ayres-Basto M, Rosengarten B, Oliveira JP: Functional transcranial Doppler: presymptomatic changes in Fabry disease. Eur Neurol. 2012, 67: 331-337. 10.1159/000337906.CrossRefPubMed Azevedo E, Mendes A, Seixas D, Santos R, Castro P, Ayres-Basto M, Rosengarten B, Oliveira JP: Functional transcranial Doppler: presymptomatic changes in Fabry disease. Eur Neurol. 2012, 67: 331-337. 10.1159/000337906.CrossRefPubMed
16.
go back to reference Jiménez-Caballero PE, Segura T: Normal values of cerebral vasomotor reactivity using the breath-holding test. Rev Neurol. 2006, 43: 598-602.PubMed Jiménez-Caballero PE, Segura T: Normal values of cerebral vasomotor reactivity using the breath-holding test. Rev Neurol. 2006, 43: 598-602.PubMed
17.
go back to reference Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS: Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). an update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012, 34: 290-296. 10.1159/000343145.CrossRefPubMedPubMedCentral Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS: Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). an update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012, 34: 290-296. 10.1159/000343145.CrossRefPubMedPubMedCentral
18.
go back to reference Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002, 39: 257-265.CrossRefPubMed Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002, 39: 257-265.CrossRefPubMed
19.
go back to reference Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE: Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010, 99: 99-108. 10.1016/j.ymgme.2009.10.004.CrossRefPubMed Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE: Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010, 99: 99-108. 10.1016/j.ymgme.2009.10.004.CrossRefPubMed
20.
go back to reference Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, et al: Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase a knockout mouse model of fabry disease. J Neurochem. 2001, 79: 1217-1224.CrossRefPubMed Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, et al: Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase a knockout mouse model of fabry disease. J Neurochem. 2001, 79: 1217-1224.CrossRefPubMed
21.
go back to reference Politei JM, Capizzano AA: Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist. 2006, 12: 103-105. 10.1097/01.nrl.0000187495.16824.a6.CrossRefPubMed Politei JM, Capizzano AA: Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist. 2006, 12: 103-105. 10.1097/01.nrl.0000187495.16824.a6.CrossRefPubMed
22.
go back to reference Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al: Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. 2001, 32: 1559-1562. 10.1161/01.STR.32.7.1559.CrossRefPubMedPubMedCentral Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al: Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. 2001, 32: 1559-1562. 10.1161/01.STR.32.7.1559.CrossRefPubMedPubMedCentral
23.
go back to reference DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, et al: Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000, 47: 229-233. 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T.CrossRefPubMed DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, et al: Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000, 47: 229-233. 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T.CrossRefPubMed
24.
go back to reference Demuth K, Germain DP: Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002, 91: 57-61.CrossRefPubMed Demuth K, Germain DP: Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002, 91: 57-61.CrossRefPubMed
25.
go back to reference Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al: Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008, 95: 163-168. 10.1016/j.ymgme.2008.06.016.CrossRefPubMedPubMedCentral Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al: Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008, 95: 163-168. 10.1016/j.ymgme.2008.06.016.CrossRefPubMedPubMedCentral
26.
go back to reference Gelderman MP, Schiffmann R, Simak J: Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol. 2007, 27: e138-e139. 10.1161/ATVBAHA.107.143511.CrossRefPubMed Gelderman MP, Schiffmann R, Simak J: Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol. 2007, 27: e138-e139. 10.1161/ATVBAHA.107.143511.CrossRefPubMed
27.
go back to reference Osborn L: Leukocyte adhesion to endothelium in inflammation. Cell. 1990, 62: 3-6. 10.1016/0092-8674(90)90230-C.CrossRefPubMed Osborn L: Leukocyte adhesion to endothelium in inflammation. Cell. 1990, 62: 3-6. 10.1016/0092-8674(90)90230-C.CrossRefPubMed
28.
go back to reference Tokuhira M, Hosaka S, Volin MV, Haines GK, Katschke KJ, Kim S, et al: Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis & Rheumatism. 2000, 43: 1122-1133. 10.1002/1529-0131(200005)43:5<1122::AID-ANR23>3.0.CO;2-7.CrossRef Tokuhira M, Hosaka S, Volin MV, Haines GK, Katschke KJ, Kim S, et al: Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis & Rheumatism. 2000, 43: 1122-1133. 10.1002/1529-0131(200005)43:5<1122::AID-ANR23>3.0.CO;2-7.CrossRef
29.
go back to reference Constans J, Conri C: Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006, 368: 33-47. 10.1016/j.cca.2005.12.030.CrossRefPubMed Constans J, Conri C: Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006, 368: 33-47. 10.1016/j.cca.2005.12.030.CrossRefPubMed
30.
go back to reference Vedder AC, Biró E, Aerts JM, Nieuwland R, Sturk G, Hollak CE: Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant. 2009, 24: 3074-3081. 10.1093/ndt/gfp263.CrossRefPubMed Vedder AC, Biró E, Aerts JM, Nieuwland R, Sturk G, Hollak CE: Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant. 2009, 24: 3074-3081. 10.1093/ndt/gfp263.CrossRefPubMed
Metadata
Title
Cerebral hemodynamics and endothelial function in patients with Fabry disease
Authors
Tomás Segura
Oscar Ayo-Martín
Isabel Gómez-Fernandez
Carolina Andrés
Miguel A Barba
José Vivancos
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2013
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-13-170

Other articles of this Issue 1/2013

BMC Neurology 1/2013 Go to the issue